Department of Emergency and Organ Transplantation, University of Bari, Policlinico, Piazza Giulio Cesare 11, Bari, Italy.
Am J Pathol. 2010 Apr;176(4):1648-59. doi: 10.2353/ajpath.2010.090276. Epub 2010 Feb 11.
Ischemia-reperfusion injury is the major cause of delayed graft function in transplanted kidneys, an early event significantly affecting long-term graft function and survival. Several studies in rodents suggest that the alternative pathway of the complement system plays a pivotal role in renal ischemia-reperfusion injury. However, limited information is currently available from humans and larger animals. Here we demonstrated that 30 minutes of ischemia resulted in the induction of C4d/C1q, C4d/MLB, and MBL/MASP-2 deposits in a swine model of ischemia-reperfusion injury. The infusion of C1-inhibitor led to a significant reduction in peritubular capillary and glomerular C4d and C5b-9 deposition. Moreover, complement-inhibiting treatment significantly reduced the numbers of infiltrating CD163(+), SWC3a(+), CD4a(+), and CD8a(+) cells. C1-inhibitor administration led to significant inhibition of tubular damage and tubular epithelial cells apoptosis. Interestingly, we report that focal C4d-deposition colocalizes with C1q and MBL at the peritubular and glomerular capillary levels also in patients with delayed graft function. In conclusion, we demonstrated the activation and a pathogenic role of classical and lectin pathways of complement in a swine model of ischemia-reperfusion-induced renal damage. Therefore, inhibition of these two pathways might represent a novel therapeutic approach in the prevention of delayed graft function in kidney transplant recipients.
缺血再灌注损伤是移植肾脏延迟功能恢复的主要原因,是一个早期事件,显著影响长期移植物功能和存活。几项啮齿动物研究表明,补体系统的替代途径在肾缺血再灌注损伤中发挥关键作用。然而,目前从人类和较大动物中获得的信息有限。在这里,我们在猪缺血再灌注损伤模型中证明了 30 分钟的缺血导致 C4d/C1q、C4d/MLB 和 MBL/MASP-2 沉积。补体抑制因子的输注导致肾小管毛细血管和肾小球 C4d 和 C5b-9 沉积的显著减少。此外,补体抑制治疗显著减少了浸润性 CD163(+)、SWC3a(+)、CD4a(+)和 CD8a(+)细胞的数量。C1 抑制剂的给予导致肾小管损伤和肾小管上皮细胞凋亡的显著抑制。有趣的是,我们报告在具有延迟移植物功能的患者中,局灶性 C4d 沉积与补体经典和凝集素途径的 C1q 和 MBL 在肾小管周围和肾小球毛细血管水平上共定位。因此,抑制这两条途径可能代表预防肾移植受者延迟移植物功能的一种新的治疗方法。